SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) to Present Additional 48-Week Data From the Phase IIb Study of Eteplirsen for the Treatment of Duchenne Muscular Dystrophy at the 17th Annual International World Muscle Society